Denali Therapeutics (DNLI) Enterprise Value (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Enterprise Value data on file, last reported at -$987.7 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$987.7 million, down 20.75% year-over-year; the trailing twelve-month figure through Mar 2026 was -$987.7 million (down 20.75% YoY), and the FY2025 annual result was -$867.9 million, down 4.27% from the prior year.
• Enterprise Value fell to -$987.7 million in Q1 2026 per DNLI's latest filing, from -$867.9 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$817.9 million in Q1 2025 and troughed at -$1.3 billion in Q4 2022.
• A 5-year average of -$1.0 billion and a median of -$957.5 million in 2022 frame the typical range for Enterprise Value.
• On a YoY basis, Enterprise Value climbed as much as 32.24% in 2022 and fell as far as 54.4% in 2022.
• A 5-year view of Enterprise Value shows it stood at -$1.3 billion in 2022, then rose by 22.58% to -$1.0 billion in 2023, then increased by 19.54% to -$832.3 million in 2024, then slipped by 4.27% to -$867.9 million in 2025, then dropped by 13.8% to -$987.7 million in 2026.
• Business Quant data shows DNLI's Enterprise Value at -$987.7 million in Q1 2026, -$867.9 million in Q4 2025, and -$848.2 million in Q3 2025.